| 2024/04/03 18:00:01 | |
|---|---|
| Price | |
| 251.282 CHF | |
| Difference | -3.23% (-8.40) |
General attributes
| ISIN | US0311621009 |
| Symbol | AMGN |
| Exchange | BX Swiss |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 133,990 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 241.747 CHF (214) |
| Ask (Ask size) | 242.232 CHF (214) |
| Open | 251.282 CHF |
| High | 251.282 CHF |
| Low | 251.282 CHF |
| Close (prev. day) | 259.678 CHF |
| VWAP | 251.282 CHF |
| Volume (pcs) | 2 |
| Trading volume | 502.50 |
| Number of trades | 1 |
| Last size | 2 |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: AMGEN INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/02/14 |
|
Global Equity Ratings |
|
| 2024/01/23 |
|
Global Equity Ratings |
|
| 2024/04/03 18:00:01 | |
|---|---|
| Price | |
| 251.282 CHF | |
| Difference | -3.23% (-8.40) |
General attributes
| ISIN | US0311621009 |
| Symbol | AMGN |
| Exchange | BX Swiss |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 133,990 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 241.747 CHF (214) |
| Ask (Ask size) | 242.232 CHF (214) |
| Open | 251.282 CHF |
| High | 251.282 CHF |
| Low | 251.282 CHF |
| Close (prev. day) | 259.678 CHF |
| VWAP | 251.282 CHF |
| Volume (pcs) | 2 |
| Trading volume | 502.50 |
| Number of trades | 1 |
| Last size | 2 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +6.41% | +18.25% | - |
| Perf (abs.) | +15.13 | +38.78 | - |
| Beta | 0.76 | 0.57 | 0.41 |
| Volatility | 44.10 | 44.79 | - |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 254.950 CHF (2) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 249.626 CHF (16) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 253.285 CHF (10) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 240.155 CHF (6) |
| YTD High | date | 268.630 CHF (2024/01/26) |
| YTD Low | date | 236.977 CHF (2024/03/08) |
| 52 Weeks High | date | 268.630 CHF (2024/01/26) |
| 52 Weeks Low | date | 198.514 CHF (2023/05/26) |
All listings for AMGEN INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/04/16 | 17:35 | 249.40 EUR | 0.17 | 22 |
| Vienna Stock Exchange | 2024/04/16 | 17:32 | 249.45 EUR | 0.00 | 3 |
| Tradegate | 2024/04/16 | 22:26 | 250.15 EUR | 0.40 | 48 |
| Stuttgart | 2024/04/16 | 21:49 | 250.00 EUR | 0.00 | 12 |
| SIX Swiss Exchange | 2022/11/14 | 17:36 | 180.00 CHF | 0.00 | 1 |
| SIX Swiss Exchange | - | - | - | 0.00 | - |
| Nasdaq | 2024/04/16 | 22:00 | 265.64 USD | 535.42 | 42,140 |
| Munich | 2024/04/16 | 08:04 | 250.80 EUR | 0.00 | 1 |
| London Stock Exchange | 2024/04/16 | 17:35 | 265.00 USD | 0.00 | 5 |
| Hong Kong Stock Exchange | 2024/02/16 | 02:15 | 1,850.00 HKD | - | - |
| Hanover | 2024/04/16 | 08:03 | 249.00 EUR | 0.00 | 3 |
| Hamburg | 2024/04/16 | 08:00 | 249.00 EUR | 0.00 | 1 |
| Frankfurt | 2024/04/16 | 16:23 | 249.00 EUR | 0.05 | 7 |
| Euronext Milan MTF Trading After Hours | 2024/03/18 | 20:28 | 250.00 EUR | 0.00 | 1 |
| Euronext Milan MTF Global Equity Market | 2024/04/16 | 17:44 | 249.15 EUR | 0.03 | 2 |
| Duesseldorf | 2024/04/16 | 19:30 | 249.05 EUR | 0.00 | 7 |
| Berlin | 2024/04/16 | 08:08 | 249.55 EUR | 0.00 | 2 |
| BX Swiss | 2024/04/03 | 18:00 | 251.282 CHF | 0.00 | 1 |
Company Logo
Contact Details
| AMGEN INC. |
| - - |
| One Amgen Center Drive - 91320-1799 Thousand Oaks |
| Telefon: +1-805-447-1000 |
| Fax: +1-805-447-1010 |
| E-mail: - |
PDF Downloads
| Company report: AMGEN INC. | |
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA. |
Members of Management Board
| Brian Druker | Member of Board of Directors |
| Michael Drake | Member of Board of Directors |
| Omar Ishrak | Member of Board of Directors |
| Robert Williams | Member of Board of Directors |
| Ronald Sugar | Member of Board of Directors |
| Tyler Jacks | Member of Board of Directors |
| Wanda Austin | Member of Board of Directors |
| Amy Miles | Member of Board of Directors |
| Charles Holley | Member of Board of Directors |
| Ellen Kullman | Member of Board of Directors |
| Greg Garland | Member of Board of Directors |
| Robert Eckert | Member of Board of Directors |
| Robert Bradway | Chairman of Managing Board |
| Annalisa Pizzarello | Member of Executive Committee |
| Anton Rabushka | Member of Executive Committee |
| Arleen Paulino | Member of Executive Committee |
| Darryl Sleep | Member of Executive Committee |
| David A. Piacquad | Member of Executive Committee |
| David M. Reese | Member of Executive Committee |
| Esteban Santos | Member of Executive Committee |
| Gilles Marrache | Member of Executive Committee |
| Ian Thompson | Member of Executive Committee |
| Jean-Charles Soria | Member of Executive Committee |
| Jerry Murry | Member of Executive Committee |
| Jonathan Graham | Member of Executive Committee |